Abstract: The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.
Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
Type:
Application
Filed:
February 20, 2024
Publication date:
September 12, 2024
Applicant:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. ROSEN, Steven Wayne RIESINGER, Lisa MCKERRACHER, Lisa BOND MORITZ
Abstract: A method includes treatment of a familial ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof in combination with a composition comprising one or more B-cell leukemia/lymphoma-2 (Bcl-2) family inhibitors. The present invention also provides methods of treating, suppressing, or inhibiting a hyperproliferative disorder or inhibiting tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof and a second composition comprising one or more Bcl-2 family inhibitors.
Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. Solid and liquid formulations of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile are described.
Type:
Application
Filed:
May 9, 2024
Publication date:
September 12, 2024
Applicant:
Genzyme Corporation
Inventors:
Jerome Arigon, Marilyn Calderone, Brigitte Illel
Abstract: The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.
Abstract: The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon and/or digital ulcers by subcutaneous or intramuscular injection of iloprost or a pharmaceutically acceptable salt or stereoisomer thereof.
Abstract: A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.
Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.
Abstract: Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.
Type:
Application
Filed:
February 5, 2024
Publication date:
September 12, 2024
Inventors:
Thomas A. MUSTOE, Robert D. Galiano, Seok Jong Hong, Ping Xie, Shengxian Jia
Abstract: Disclosed are methods of treatment of neuropathic pain such as fibromyalgia induced neuropathic pain by use of patches, simultaneously, on the top and the bottom of a foot of an individual where the patches contain a formulation topically applied to the skin of the foot.
Abstract: Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
Abstract: The present invention relates to a method of treating or preventing a viral disease or viral infection comprising administering to a subject a compound of formula (I) or formula (II)
Type:
Application
Filed:
June 27, 2022
Publication date:
September 12, 2024
Inventors:
Johan Auwerx, Adrienne Mottis, Mark Nelson
Abstract: The present invention is directed to use of cannabidiol and compositions thereof as preventive and curative agent for IBH. The invention is further directed to related methods and compositions.
Abstract: Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin of a subject and uses of a topical cannabinoid formulation provided herein for the treatment of a skin disease or condition in a subject.
Type:
Application
Filed:
March 7, 2022
Publication date:
September 12, 2024
Applicant:
Avicanna Inc.
Inventors:
Aras Azadian, Satish Asotra, AKM Abdul Hai
Abstract: Described herein are compositions which can be used to improve circulation and thereby treat ailments of diabetic patients. The compositions comprise a cannabinoid, preferably cannabidiol. Further described herein are compositions comprising a cannabinoid, and a blood flow enhancing agent. Methods for treatment of diabetic patients are also disclosed.
Abstract: The present disclosure relates to the use of suitable phytocannabinoids such as cannabidivarin, cannabinol, cannabigerol, cannabidiol, delta9-tetrahydrocannabinol, cannabichromene, or combinations with or without cannabidiol thereof for treatment endometrial cancer and endometriosis and/or similar conditions, diseases, or disorders.
Type:
Application
Filed:
July 12, 2022
Publication date:
September 12, 2024
Inventors:
Massimo NABISSI, Oliviero MARINELLI, Cristina AGUZZI, Laura ZEPPA, Maria Beatrice MORELLI
Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.
Type:
Application
Filed:
October 23, 2023
Publication date:
September 12, 2024
Inventors:
Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
Abstract: The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.
Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses.
Abstract: The invention provides methods of treating long COVID in a patient in need thereof, comprising administering to said patient a composition comprising a therapeutically effective amount of at least one human milk oligosaccharides, wherein such treatment reduces or improves at least one sign or symptom of long COVID.
Abstract: The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. These new syntethic molecules differ from other similar agonists due to the simplicity of the formula, the ease and cheapness of preparation and the possibility of further chemical processing to modify the physicochemical properties and allow conjugation to other molecules (for example protein antigens).
Type:
Application
Filed:
July 19, 2022
Publication date:
September 12, 2024
Inventors:
Francesco PERI, Alessio ROMERO, Simona D'AMATO
Abstract: Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating macular degeneration, wherein the pharmaceutical composition contains aucubin.
Type:
Application
Filed:
December 9, 2020
Publication date:
September 12, 2024
Applicant:
INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY
Abstract: There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability.
Type:
Application
Filed:
January 27, 2022
Publication date:
September 12, 2024
Inventors:
Michael Kevin BAMAT, Yi GAO, Jeffrey A. MILLER, Yihong QIU
Abstract: Methods of use and compositions comprising a source of adenosine-5?-triphosphate (ATP) are provided. The administration of the compositions described improves cognitive function, reaction times, focus, mood, neuromuscular reactivity, and/or optimizes mental performance.
Type:
Application
Filed:
June 22, 2022
Publication date:
September 12, 2024
Inventors:
John RATHMACHER, Larry KOLB, Shawn BAIER
Abstract: Use of inosine in preparing a drug for the treatment of coronavirus disease 2019 (COVID-19), where a formulation of the drug includes one or more selected from the group consisting of tablets, capsules, oral liquid preparations, emulsions, and injections. Inosine can reduce level of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) induced interleukin-6 (IL-6), alleviate SARS-COV-2 caused inflammatory lung injury, and further increase the percent survival of critically ill patients with SARS-COV-2.
Abstract: The present invention relates to a composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded miRNA as an active ingredient and, more specifically, to: miR-3139, miR-3189, miR-3199 or miR-8485, which are double-stranded miRNA; a double-stranded oligonucleotide structure comprising same; or a pharmaceutical or cosmetic composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising nanoparticles containing the structure as an active ingredient. A composition according to the present invention can prevent hair graying and reduce the rate of progress thereof by activating melanocytes and promoting melanogenesis and can allow the hair already affected by graying to be improved to a state before graying.
Type:
Application
Filed:
February 25, 2022
Publication date:
September 12, 2024
Inventors:
HAN OH PARK, SANG KYU LEE, OH SEUNG KWON, EUN AH GOH
Abstract: Provided are diagnosis and treatment methods of autism spectrum disorder, based on an activity regulation mechanism of quiescent neural stem cells, and use thereof.
Type:
Application
Filed:
December 31, 2021
Publication date:
September 12, 2024
Applicant:
DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Jongpil KIM, Hongwon KIM, Byounggook CHO
Abstract: TNF-alpha (Tumor Necrosis Factor-alpha) is a cytokine, a protein involved in the inflammation process in the body. It plays a crucial role in the immune system, primarily produced by activated macrophages the white blood cells. TNF-alpha is critical in the inflammatory response to infections and diseases, but it can also contribute to inflammatory and autoimmune diseases when produced in excess. Many antibodies are created to inhibit over-expressed TNF-alpha but with serious side effects. The present invention provides a mRNA vaccine to reduce the titer of TNF-alpha, leading to treating multiple life-threatening diseases including but not limited to rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis, inflammatory bowel disease, type 2 diabetes, tumor progression, angiogenesis, and metastasis, heart failure from myocardial cell death, and atherosclerosis from fibrosis.
Type:
Application
Filed:
January 7, 2024
Publication date:
September 12, 2024
Applicant:
RNA Therapeutics, Inc.
Inventors:
Sarfaraz K. Niazi, Matthias Magoola, Zafeer Ahmad
Abstract: The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.
Type:
Application
Filed:
July 19, 2023
Publication date:
September 12, 2024
Inventors:
Shawn A. SCRANTON, Colin Richard GREEN, Brian LEVY
Abstract: A Lyophyllum decastes polysaccharide, a preparation method and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The preparation method includes the following steps: (1) adding an aqueous solution containing EDTA-2Na into a fruiting body of Lyophyllum decastes, performing ultrasonic treatment, and then performing water extraction treatment to obtain an extractive solution; (2) concentrating the extractive solution, adding anhydrous ethanol for precipitation, followed by centrifuging to obtain precipitates, then obtaining a crude Lyophyllum decastes polysaccharide; and (3) conducting removal of proteins and dialysis of the crude Lyophyllum decastes polysaccharide to obtain the Lyophyllum decastes polysaccharide.
Type:
Application
Filed:
December 28, 2023
Publication date:
September 12, 2024
Inventors:
Qi WANG, Ling SU, Yan ZHANG, Yu LI, Min GAO, Xueyu SHANG, Tianci WANG
Abstract: Ester and sulfated derivatives of hyaluronic acid are described for use in the prevention and treatment of the initial stage of SARS-CoV-2 disease.
Abstract: A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %: wherein R1 to R6 are as defined herein.
Abstract: The present invention relates to compositions and methods useful for immune activation that is effective for eliciting a non-antigen-specific immune response in a subject. An immunomodulator composition can include a therapeutically effective amount of a liquid nitric oxide releasing solution (NORS) for eliciting an immune response in a subject to treat an adverse health condition in the subject.
Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.
Abstract: The present invention relates to a composition for preventing, treating or improving calcium-related degenerative diseases, osteoporosis or cancers, which includes Sigma Anti-bonding Calcium (SAC) gluconate as an active ingredient, and more particularly, to a composition for preventing, treating or improving calcium-related degenerative disease such as osteoporosis, as well as osteoporosis, generation of neoplasm such as malignant tumors, cancers, or the like, that provides calcium ions without side effects on cells through a calcium channel and glucose transport thus to normalize cellular metabolism and prevent degeneration thereof.
Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.
Type:
Application
Filed:
May 2, 2024
Publication date:
September 12, 2024
Applicant:
American Regent, Inc.
Inventors:
Gopal Anyarambhatla, Richard Lawrence, Jasmina Marinkovic
Abstract: The present invention relates to a method of preventing or treating chronic pain comprising administering to a subject, in an amount/number effective to elicit, sustain or potentiate an inflammatory process, a pro-inflammatory compound, myeloid leukocyte cells or a substance that increases the number or activity of myeloid leukocyte cells.
Type:
Application
Filed:
March 10, 2023
Publication date:
September 12, 2024
Inventors:
Luda DIATCHENKO, Jeffrey MOGIL, Lucas Vasconcelos LIMA, Marc PARISIEN, Massimo ALLEGRI, Nader GHASEMLOU, Mohamad KARAKY
Abstract: The disclosure features amphiphilic ligand conjugates including a peptide or a ligand for a mucosal-associated invariant T-cell and a lipid and T cell receptor modified immune cells. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of T cell receptor expressing cells.
Abstract: The disclosure relates generally to ligand-based chimeric antigen receptor (CAR) cells. More specifically, the CAR cells express B-cell activating factor (BAFF) protein for recognition by a receptor of BAFF on the surface of a cell. CAR cells can include cytotoxic T lymphocytes, natural killer (NK) cells or natural killer T (NKT) cells that express a chimeric receptor that recognizes a receptor of BAFF. The disclosure further relates to methods of treating a variety of conditions, such as cancers and autoimmune diseases, using the disclosed CAR cells.
Abstract: Embodiments of the present disclosure relate to compositions and methods of enhancing anti-tumor activities of modified cells, the method comprising: administering an effective amount of the modified cells to a subject having a solid tumor; and administering an effective amount of an agent to the subject, the agent comprising rapamycin, wherein the modified cells inhibit growth of the solid tumor in the subject, and wherein the anti-tumor activities in the subject are greater than those in a subject that is administered with an effective amount of modified cells but without the agent.
Type:
Application
Filed:
February 14, 2024
Publication date:
September 12, 2024
Applicants:
Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
Inventors:
Chengfei Pu, Dongqi Chen, Xiaogang Shen, Le Tian
Abstract: The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Hyper-lgE syndrome (HIES). In particular, the present invention provides means and methods for genetically modifying HSCs or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides populations of engineered HSCs or T-cells which comprise cells comprising an exogenous polynucleotide sequence comprising at least a partial or complete sequence of a functional STATS gene, said exogenous polynucleotide sequence being integrated in an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), resulting in the expression of a functional STATS polypeptide.
Type:
Application
Filed:
May 20, 2022
Publication date:
September 12, 2024
Inventors:
Toni Cathomen, Tatjana Cornu, Viviane Dettmer-Monaco, Simone Haas, Julia Rositzka, Philippe Duchateau, Alexandre Juillerat
Abstract: The present invention relates to a medicament for use in a method of preventing or treating cancer in a patient, wherein the medicament comprises at least two of the following populations of cells (i) to (iv): (i) a population of lymphokine-activated killer cells (LAKs), (ii) a population of cytokine-induced killer cells (CIKs), (iii) a population of ??-T-cells, (iv) a population of tumor-specific T-cells (CTLs), wherein the population of cells in (i) to (iv) are derived from autologous cells from said patient or from allogeneic cells from a donor, and pharmaceutical composition, kit or kit-of-parts related thereto.
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
March 8, 2024
Publication date:
September 12, 2024
Inventors:
Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
Abstract: Disclosed are compositions and methods for targeted treatment of myeloid and B cell malignancies. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill myeloid and B cell malignancies with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a myeloid and B cell malignancies that involves adoptive transfer of the disclosed CAR T cells.
Abstract: The present disclosure provides method of detecting senescent cells in a cell sample and methods of treating a disease, disorder, or condition associated with senescence in a subject by administering at least one senolytic agent to the subject.
Type:
Application
Filed:
October 10, 2023
Publication date:
September 12, 2024
Inventors:
Johnny HUARD, Marc Joseph PHILIPPON, Sudheer Kumar RAVURI, William Sealy HAMBRIGHT, Charles HUARD, Michael Terrance MULLEN, II, John Weston MITCHELL, Kaitlyn Elizabeth WHITNEY